Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update
Announces strategic reprioritization to focus on clinical development of MT-6402, MT-8421, and MT-0169, and preclinical…
Announces strategic reprioritization to focus on clinical development of MT-6402, MT-8421, and MT-0169, and preclinical…
Total revenue of $27.30 million for the full year of Fiscal 2022, an increase of…
HOUSTON–(BUSINESS WIRE)–Microvast Holdings, Inc. (NASDAQ: MVST), (“Microvast” or the “Company”), a technology innovator that designs,…
Enabling self-service monitoring and optimization for Snowflake customers FRISCO, Texas–(BUSINESS WIRE)–#elitepartner—kipi.bi, a modern data engineering,…
PALO ALTO, Calif.–(BUSINESS WIRE)–#buyerintelligence–Humantic AI, the world’s first buyer intelligence platform, leverages cutting-edge AI to…
New offering allows AWS customers to deploy and run modern applications on Kubernetes SAN FRANCISCO–(BUSINESS…
BELLEVUE, Wash.–(BUSINESS WIRE)–PACCAR announced today that it has made a minority equity investment in its…
The highly competitive Batch 15, which saw a 120% increase in applicants from the previous…
SAN CARLOS, Calif.–(BUSINESS WIRE)–$PRST—Presto Automation Inc. (Nasdaq: PRST), one of the largest drive-thru automation technology…
Enterprise Connect 2024 Takes Place March 25-28 in Orlando, FL SAN FRANCISCO–(BUSINESS WIRE)–Enterprise Connect, the…
SALINAS, Calif., March 30, 2023 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL;…
Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31,…
Company announcement – No. 11 / 2023 Zealand Pharma announces completion of a directed issue…
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery…
– Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with…
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b…
All Cohort 1 leukemia patients have maintained durable morphological complete responses (CR) beyond 18 months…
Fortress expects to file a total of three new drug applications in 2023 Record consolidated…
REDWOOD CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”),…
Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May…